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Summary 
Background Insight into the mechanisms of organ engraftment 
and acquired tolerance has made it possible to facilitate these 
mechanisms, by tailoring the timing and dosage of immuno-
suppression in accordance with two therapeutic principles: 
recipient pretreatment, and minimum use of post-transplant 
immunosuppression. We aimed to apply these principles in 
reCipients of renal and extrarenal organ transplants. 
Methods 82 patients awaiting kidney, liver, pancreas, or 
intestinal transplantation were pretreated with about 5 mg/kg 
of a broadly reacting rabbit antithymocyte globulin during 
several hours. Post-transplant immunosuppression was 
restricted to tacrolimus unless additional drugs were needed 
to treat breakthrough rejection. After 4 months, patients on 
tacrolimus monotherapy were considered for dose-spacing to 
every other day or longer intervals. 
Findings We frequently saw evidence of immune activation in 
graft biopsy samples, but unless this was associated with graft 
dysfunction or serious immune destruction, treatment usually 
was not intensified. Immunosuppression-related morbidity was 
virtually eliminated. 78 (95%) of 82 patients survived at 1 year 
and at 13-18 months. Graft survival was 73 (89%) of 82 at 
1 year and 72 (88%) of 82 at 13-18 months. Of the 
72 recipients with surviving grafts, 43 are on spaced doses of 
tacrolimus monotherapy: every other day (n=6), three times 
per week (11), twice per week (15), or once per week (11). 
Interpretation The striking ability to wean immunosuppression 
in these recipients indicates variable induction of tolerance. 
The simple therapeutic principles are neither drug-specific nor 
organ-specific. Systematic application of these principles 
should allow improvements in quality of life and long-term 
survival after organ transplantation. 
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Introduction 
Early loss of organ allografts to acute rejection has been 
almost eliminated by use of combinations of potent 
immunosuppressive drugs. However, chronic rejection 
has remained an unresolved problem. Furthermore, 
maintenance immunosuppression has continued to cause 
late morbidity and mortality. The ideal solution would be 
to make recipients tolerant to donor tissues. 
We have suggested that extended organ engraftment 
under conventional immunosuppression is, in fact, a 
manifestation of partial tolerance, I l and that this 
tolerance could be made more complete by observation of 
two therapeutic principles:4 recipient pretreatment; and 
the least possible use of post-transplant immuno-
suppression. We aimed to systematically apply these 
principles in recipients of organ transplants. 
Methods 
Participants and protocol 
Between July, 2001, and November, 2001, we recruited 
patients awaiting transplantation of the kidney, liver, 
intestine, or whole pancreas for whom there was sufficient 
time for pretreatment before transplantation. We excluded 
those who had insufficient time for pretreatment. 
The regimen of immunosuppression was submitted to 
the University of Pittsburgh institutional review board, 
which judged it to be within the boundaries of standard 
treatment. The protocol was then remanded to the 
Presbyterian University Hospital innovative practices 
committee and to the pharmacy and therapeutics 
committee, with approval by both. All patients provided 
standard informed consent. In addition, separate informed 
consent was obtained for studies of immune variables not 
routinely obtained in our conventional practice. Data 
integrity, and safety and efficacy monitoring, were assured 
by establishment of a formal review every week of all cases. 
Procedures 
The generic protocol (all organs) stated a need for 
pretreatment with an infusion of 5 mg/kg of a broadly 
reactive rabbit antithymocyte globulin (thymoglobulin; 
Sangstat, Menlo Park, CA, USA) over the several hours 
immediately preceding transplantation; we gave 
participants 1-2 g methylprednisolone concomitantly to 
prevent cytokine reactions. Twice-daily mono therapy with 
tacrolimus was begun the day after transplantation, with a 
target trough concentration of 10 j-Lg/L. We added other 
agents (prednisone, sirolimus, muromonab-CD3) as 
needed for control of rejection, and for as brief a period as 
possible. 
To encourage protocol adherence, we explained the 
treatment rationale to workers in the clinical services in 
formal educational sessions throughout the accrual of 
cases. Despite these efforts, violations of the therapeutic 
algorithm were not rare, especially in the pancreas and 
intestine subgroups. Principal violations consisted of 
either systematically obtaining high trough concentrations 
of tacrolimus or adding multiple drugs to tacrolimus 
during the early post-transplant period. In some cases, the 
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monitoring committee promptly aborted escalation of 
immunosuppression, which was not possible in other 
cases because of opposition by the clinical team. Even 
when a protocol violation was thought by consensus to 
have taken place, no cases were eliminated from analysis. 
Beginning at 4 months, patients who had been on 
tacrolimus monotherapy for the preceding 60 days were 
considered for weaning. After obtaining a satisfactory 
graft biopsy sample, we consolidated the twice-daily doses 
of tacrolimus to one daily dose for a few days or weeks. 
We then spaced the daily doses to every other day and 
subsequently to longer intervals in selected individuals. In 
patients whose spacing reached one dose per week, we did 
not advise drug discontinuance. 
We terminated weaning if rejection was diagnosed on 
the basis of substantial deterioration of graft-specific 
function tests, and confirmed by biopsy samples showing 
an unacceptable amount of immune activation or 
destruction. If abnormalities were not promptly reversed 
by steroid bolus treatment, we resumed daily tacrolimus. 
If necessary, late rejections were treated by addition of 
short courses of other agents as needed, in the same way 
as for treatment of early post-transplant rejection. After 
re-establishing control, resumption of spaced weaning was 
considered. The intent throughout was to find the 
minimum amount of immunosuppression consistent with 
the avoidance of irreversible graft damage. 
Immunological monitoring was not used to guide 
weaning. However, in kidney recipients with more than 
1 year follow-up, we did in-vitro studies: mixed lymphocyte 
reactivity, cytotoxicity-mediated lysis, limiting dilution 
assay for donor-specific precursor cytolytic T cells, and the 
ELISPOT test for frequency of 'Y-interferon-producing cells 
(Mabtech, Cincinnati, OH, USA). 
We obtained graft biopsy specimens for suspicion of 
rejection, or before weaning. In addition to conventional 
haematoxylin and eosin histopathology, we used special 
stains when indicated to study blood vessels (Verhoff van 
Gieson), quantify extent of interstitial fibrosis (Masson 
Trichrome), or visualise other points of interest. When the 
donor and recipient were of opposite sexes, we analysed 
lymphoid collections in the biopsy samples by in-situ 
hybridisation, with X and Y chromosome probes. We 
placed a few specimens in optimum cold-temperature 
compound (Miles Laboratory, Elkhart, IN, USA) and 
snap froze them for delineation of donor and recipient 
HLA phenotypes with immunocytochemical methods. 
We coded biopsy findings into standardised organ-
specific categories-eg, the Banff system for the kidneyS 
and the modified Banff system for the liver' and other 
organs. In the kidney classification, the ascending scale of 
rejection is: 0 (none), BL (borderline), lA (mild), lB 
(mild), 2A (moderate), 2B (moderate), and 3 (severe). 
We then developed a rejection profile for each of the 
first 12 months for the entire population of kidney 
recipients. Patients with no biopsy samples and no clinical 
evidence of rejection were deemed rejection-free. When 
we obtained biopsy specimens we gave them Banff grades 
on a scale of absent to severe rejection, using the worst 
score in a given month for graphic display if multiple 
biopsy procedures took place in that month. Similar 
analyses were done for the other kinds of organ recipients. 
Statistical analysis 
We expressed graft function and other variables as mean 
(SD). We compared relevant subgroups with analysis of 
variance and t tests. No patients were lost to follow-up 
during the 13-18 months of post-transplant observations. 
Because of unequal starting times (early and late July, 
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2001), maximum follow-up was 18 months for the 
intestine and pancreas recipients and 17 months for the 
liver and kidney recipients. 
We delineated populations into four categories in 
accordance with treatment after transplantation that was 
deemed necessary by members of the clinical service. 
Category 1 consisted of patients in any given month who 
received no drug other than tacrolimus. Patients in 
category 2 had additional one or two boluses of 
methylprednisolone. In category 3, we added either three 
or more steroid boluses to baseline tacrolimus, or gave a 
short course of oral prednisone or sirolimus. Category 4 
consisted of recipients who were on daily double-drug or 
triple-drug immunosuppression for at least half the 
stipulated month-eg, tacrolimus and sirolimus with or 
without prednisone or additional antibody treatment. 
We superimposed the percentage of weaning patients on 
a graphic treatment summary, thus showing the correlation 
of overall treatment with weaning. The reference group 
consisted of kidney recipients. Since data elements are not 
organ specific, similar summaries for recipients of liver and 
other kinds of extrarenal organ allografts could be 
produced for independent study or for comparison with 
the kidney transplant reference population. 
Role of the funding source 
There was no external sponsor of the study, which was 
designed, initiated, and managed by the authors, who were 
responsible for data collection, data analysis, preparation of 
the report, and the decision to submit it for publication. 
Results 
We recruited 103 adults awaiting transplantation; entry 
was precluded for 21 recipients because not enough time 
was available for pretreatment. Thus, we studied 
82 patients (50 kidney, 17 liver, 14 pancreas, 11 bowel; 
ten patients received kidney and pancreas transplants). 
35 (43%) of the 82 recipients had an adjunct infusion of 
1·9-9·1 X los/kg donor bone marrow cells; this cohort was 
defined by availability of bone marrow cells. 
Pretreatment effects 
Similar to results of extensive studies in non-human 
primates," antithymocyte globulin induced a striking fall 
of all T-cell subsets to near zero within a few hours in all 
kinds of organ recipients and a less pronounced fall of 
other peripheral mononuclear cells, neutrophils, and 
platelets. Striking T-cell depletion of recipient lymph 
nodes sampled at surgery was also noted. Recovery of 
peripheral blood changes began in 1 or 2 weeks and 
was complete by 6 months. Well-known side-effects of 
antilymphoid globulins were noted, including chills, 
fever, headaches, diarrhoea, abdominal pain, shortness 
of breath, and hypotension or hypertension, which 
responded to treatment. 
n Patients' Graft Creatinine 
survival survival (fLmoIfL; 
mean [SD]) 
Category 
Cadaver kidney 
Alone 30 30(100%) 28 (93%) 168·0 (61·9) 
With pancreas 10 10 (100%) 10 (100%) 150·3 (17·7) 
Live donor kidney 10 9 (90%) 9 (90%) 150·3 (88-4) 
Total 50 49 (98%) 47 (94%) 159·1 (61·9) 
Table 1: 13-17 month patients' and kidney graft survival and 
i-year serum creatinine in the 47 recipients with functioning 
grafts 
1503 
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n Patients' Graft Creatinine 
survival at survival at (fLmol/l; 
13-17 months 13-17 months mean [SO]) 
at 1 year 
Cadaver kidney 
No bone marrow 20 20 (100%) 
Bone marrow 20 20 (100%) 
-----
19 (95%) 
19 (95%) 
154· 7 (56·6) 
169· 7 (80,4) 
Table 2: Cadaver kidney transplantation without and with 
donor bone marrow infusion 
Kidney transplantation 
Mean age of the 50 kidney recipients was 52·5 years (SO 
13'2); these patients were not selected low-risk patients. 
Eight (16%) were undergoing retransplantation . Of the 
50 kidney allografts, 40 were obtained from cadavers and 
the remaining ten were from unrelated (n=3) or related 
(7) live donors . Mean age of the adult cadaver donors was 
49·9 years (SO 10'1), indicating both the ageing 
population of Pittsburgh and the need to systematically 
use marginal organs. Ten of the 40 recipients of cadaver 
kidneys also were given the donor pancreas (see below). 
20 kidney recipients had 1,9- 9,1 X 108/kg donor bone 
marrow cells infused within 24 h after organ 
implantation.8 Of the six HLA antigens tested, a mean of 
3·6 (SO 1'7) were mismatched (range 0-6). No positive 
lyrnphocytotoxic crossmatches were reported, but seven 
(14%) recipients were presensitised-ie, panel-reactive 
antibodies greater than 20%. 
After 13-17 months, survival of patients who received a 
kidney transplant was 49 (98%) of 50, with graft survival 
of 47 (94%). A complication of anaesthesia led to the only 
death (after 2 days) in this group, with loss of a live donor 
graft. Two cadaveric kidneys were lost--one to a delayed 
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Figure 1: Course of treatment of a cadaveriC-kidney recipient 
Biopsy-proved rejection (Banff lA) in the third week was treated with 
boluses of 1-0 g and 0·5 g prednisone. Similar findings in later biopsy 
specimens were not associated with renal funct ion changes and were not 
treated. Instead , weaning was begun at 7 months. At 16·5 months. 
treatment was one dose per week tacrolimus. 
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Figure 2: Biopsy specimen of cadaveric-kidney transplant 
(Left) Needle biopsy sample of the allograft in figure 1 at 4 months; 
haematoxylin and eosin staining X40. (Right) Banff grade lA (mild) 
rejection; haematoxylin and eosin staining x200. Repeat biopsy 
speCimens taken in subsequent months were closely similar. 
Shwartzman reaction' after 90 days. The other loss 
happened at 240 days, mainly because of progression of 
donor disease that was present in a pretransplant wedge 
biopsy sample. Patients' survival to date, graft survival, 
and I-year serum creatinine concentrations did not differ 
significantly between the cadaver kidney alone, kidney 
with pancreas, and live-donor subgroups (table 1). These 
results were not affected by additional donor bone-
marrow cell infusion (table 2). 
Spaced dosing was instituted 3·9-11·9 months after 
transplantation in 39 (83%) of the 47 renal recipients. 
Doctor's or patient'S anxiety about spaced dosing 
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Figure 3: Course of treatment of a cadaveric-kidney reCipient 
with pre-existing nephropathy 
Five biopsy specimens taken over a period of 10 months had Banff 
rejection grades of either borderline or 1, prompting steroid boluses. 
Tacrolimus doses were first reduced from daily to two times per week 
(months 6·5-10), then temporarily restored to daily, and eventual ly 
established at three times per week. 
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frequently delayed its initiation, especially when cadaveric 
grafts had ischaemia-reperfusion injury and poor primary 
function. In other cases, histopathological evidence of 
immune activation in the preweaning biopsy specimen 
caused procrastination by the clinical staff. In one patient, 
for example, a clinical and biopsy-proved Banff 1A (mild) 
rejection after 20 days was treated with two boluses of 
methylprednisolone (figure 1). When further biopsy 
samples in the 3rd and 4th month showed continued 
Banff 1A rejection (figure 2), weaning was not started. No 
additional treatment was given, however, because renal 
function was stable. Despite similar histopathological 
findings at 7 months, spacing of tacrolimus doses to every 
other day was begun, and by the end of the year the dose 
frequency was one per week (figure 1). 
In 25 (64%) of the 39 kidney recipients in whom 
weaning was begun, intermittent dosing has now been 
administered for 5-11 months (mean 9 [SD 1· 5]), without 
(n=21; figure 1) or with (4; figure 3) short interruptions. At 
14-17 months post-transplantation, the dose intervals of 
these 25 patients were every other day (n=l), three times a 
week (6), two times a week (11), and once a week (7). 
Rate of weaning was different in kidney-alone and 
kidney-pancreas recipients. \X'eaning was attempted in 
29 (78%) of 37 recipients of kidney-alone grafts, and 
remained in effect in 21 (72%) of these at 13-18 months. 
By contrast, spaced weaning that began at comparable 
postoperative times in all ten kidney-pancreas recipients 
was continued in only four (40%). These kidney-pancreas 
reCIpIents still on weaning began dose-spacing 
4-11 months after transplantation, and after a further 
4-11 months, the dose frequency was three times per 
week (n=3) or once per week (1). All four patients have 
serum creatinine concentration less than 132·6 fLmol/L. 
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In eight kidney-alone recipients in whom weaning was 
suspended, time from transplantation to start of dose 
spacing was 5,5-11,9 months (mean 8·1 [SD 2'7]), and 
duration of weaning was 1·9-9·0 months (5'0 [2·7]). The 
primary reason for return to daily treatment was a rise of 
serum creatinine from a mean of 159 [26'5] fLmollL (range 
114'9-203'3) to a peak of 336 [194'5] fLmol/L (range 
141'4-707 '2). Renal biopsy samples taken at the same time 
had borderline or Banff 1 rejection grades. All eight patients 
were treated by resumption of daily tacrolimus (or in one 
patient its replacement by daily sirolimus), and temporary 
addition of other immunosuppressants as needed. In seven 
of the eight patients, serum creatinine concentrations were 
promptly restored to baseline (range 114'9-221'0) with 
commensurate reduction in Banff biopsy sample scores. 
Serum creatinine concentration in the exceptional patient 
rose, despite treatment, to 663 fLmollL. The patient 
remained dialysis-free at 17 months. Chronic nephropathy, 
which was the dominant finding in multiple biopsy 
samples, had been present in pretransplant wedge biopsy 
specimens of both kidneys of the cadaver donor. After 
following a similar course, the mate kidney failed after 
240 days. 
In the six patients who underwent kidney and pancreas 
transplantation and who did not continue weaning of 
tacrolimus, the retreat from weaning after dose-spacing 
for 1-7-5 months was prompted by rises in serum lipase 
rather than in serum creatinine or by loss of pancreas 
function. Lipase changes were viewed with alarm, and 
precipitated mUltiple kidney and pancreas biopsy 
procedures. When evidence of mildly destructive immune 
activation was reported in one or the other organ (or 
both), daily tacrolimus was resumed and second and third 
drugs were added for lengthy periods. During the 
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Figure 4: Four categories of treatment in the first :1.2 months for 47 kidney reCipients whose grafts stili function after 
:1.3-:1. 7 months 
Numbers represent category of treatment. 81-90% of patients in any given month were on tacrolimus monotherapy (category 1) or nearly so 
(category 2 and 3) 
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succeeding months, serum creatinine concentrations rose 
in four patients from previously normal amounts-in one 
patient to 442 /-lmollL. 
Figure 4 is a month-by-month summary of the 
immunosuppression during the first 12 months of the 
47 kidney recipients (of the starting 50), whose renal 
grafts still functioned. In each of the first 12 months, 
38-42 (81-90%) of recipicnts were on tacrolimus 
monotherapy (category 1) or nearly so (categories 2 and 
3). The other five to nine patients had multiple drug 
treatment during months 3-12 and were in category 4. 
Five of the nine also had been treated with multiple drugs 
during the first 30-60 days, and thus were in category 4 
from the outset. Early use of multiple agents in category 4 
patients usually indicated a compulsion to treat-ie, a 
protocol violation-rather than a genuine indication for 
intensified immunosuppression. For example, the 
cadaveric kidney in the patient depicted in figure 5 
functioned poorly at first because of biopsy-documented 
severe reperfusion injury. By the third week, further 
biopsy samples also showed evidence of mild (Banff 1 A) 
rejection. Because of the clinical team's conviction that 
recovery from the combined insult could not take place 
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Figure 5: Protocol violation in recipient of a cadaver kidney 
that sustained a severe ischemia-reperfusion injury 
Daily sirolimus (doses stacked on tacrolimus doses) and prednisone 
boluses plus daily steroid treatment were added to tacrolimus in the third 
week because of biopsy findings of mild (Banff 1Al rejection, A return to 
tacrolimus monotherapy after 7 months was succeeded by a Banff 2A 
(moderate) rejection and restoration of multiple drug immunosuppression. 
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without heavy immunosuppression, continuous sirolimus 
and prednisone were added to tacrolimus. The kidney did 
recover, but efforts to return to tacrolimus monotherapy 
7 months later led to rejection. On Jan 1,2003, 39 (83'/\) 
of the 47 patients with functioning kidneys-including 25 
on spaced weaning-were receiving one drug: tacrolimus 
(n=32) or sirolimus (7). Three were on double-drug 
treatment with tacrolimus and prednisone (n=2) or 
mycophenolate mofetil (1), whereas five were on triple-
drug regimens. 
Immunological studies were done on ten kidney 
recipients with more than 1 year follow-up. Seven of the 
ten recipients had been on spaced doses of tacrolimus for 
6-10 months, One of the other three was receiving daily 
tacrolimus, and two (including the patient depicted in 
figure 5) were on multiple drugs. By mixed lymphocyte 
reactivity testing, the two patients with daily multiple drugs 
had near total suppression of responses to donor and third-
party alloantigens, and to mitogens, By contrast, results of 
the mixed lymphocyte reactivity assay showed retention of 
vigorous responses against third-party alloantigens and 
mitogens by all seven patients on spaced tacrolimus doses 
and by the patient on daily tacrolimus. Moreover, donor-
specific responses were fully intact by mixed lymphocyte 
reactivity testing in six of these eight patients. Further 
studies were done in five of these recipients. In three, 
cytotoxicity-mediated lysis assay showed 0, 0, and 2% 
donor-cell killing; in all three, the frequency of precursor 
cytolytic T cells was shown by the limiting dilution assay to 
be fewer than 11300 000. Cell-killing was low (10% and 
15%) in the other two patients with frequencies of 
precursor cytolytic T cells of 1/60 000 and 1/150 000. 
ELISPOT tests were done in two of the five patients. Both 
recipients had a very low frequency of 'Y-interferon cells in 
response to donor-specific stimulation. 
The frequency of biopsy specimens generated by 
clinical suspicion of rejection was greatest during the first 
30 days (figure 6). During this period and throughout the 
rest of the year, most diagnosed rejections were graded as 
borderline or Banff 1. The renal graft that survived the 
coagulopathy of an aborted intraoperative Shwartzman 
reaction had a deceptively encouraging first biopsy 
sample, but developed complete cortical necrosis at 
90 days (figure 6). The recipient who received the graft 
with pre-existing severe nephropathy had worsening of 
this underlying pathology before loss of the graft at 
240 days, but with only mild acute rejection. 
As experience of the clinical team accumulated, 
secondary immunosuppressants were not added to 
tacrolimus in response to most bordeline grades and many 
Banff 1 scores if renal function was stable and no other 
clinical evidence of rejection was present. In many 
putative benign biopsy samples, lymphoid aggregates were 
present with nearby low-grade tubuli tis, but with normal 
intervening tissue. The finding is typified by the 4-month 
biopsy specimen (figure 2) that caused the weaning delay 
for the patient whose course is shown in figure 1. In 
16 biopsy samples from 14 patients, the lymphoid 
aggregates in grafts from opposite-sex donors were 
analysed by X and Y chromosome probes: in 11 of the 
biopsy samples, 1-9% of cells were donor-derived. The 
aggregates in figure 2 were 9% donor. 
Liver transplantation 
17 patients received liver transplants for chronic end-stage 
hepatic disease. ABO-identical allografts were obtained 
from 15 cadavers and two live volunteers. The mean 
number of HLA mismatches was 4·4 (SD 1· 3), and in one 
case, the lymphocytotoxic crossmatch was positive. Four 
THE LANCLT· Vol 361 • May 3, 2003· www.thelancet.com 
Number of 
patients 
BANFF 3 
BANFF 2B 
BANFF 2A 
BANFF 1B 
BANFF 1A 
Borderline 
No ACRj 
no biopsy 
sample 
50 49 
• 
• 
.. ~ ... 
• • • • • • 
• • 
• 
• • • 
• i •• 
•• 
•• • 
o 1 
• 
• 
• 
2 
49 48 48 48 
@ 
• • • 
• • 
• 
@ 
• • 
i 
• 
•• • • •• i@. •• 
'. . • • •• 
• 
• • 
3 4 5 
ARTICLES 
48 48 47 47 47 47 
• • 
• 
• • 
• • 
• • • • • .i • • i 
___ L ! • • 
-r • • • 
i 
.1 • 
• • • • • • • • 
• 
• • . ., . 
~"~,-,-j 
.eI 
• • 
• 
• 
6 7 8 9 10 11 12 
Post transplant (month) 
Figure 6: Banff grades of allograft biopsy specimens obtained In 50 kidney recipients 
Solid circles represent recipients in whom biopsy sample was taken, Small open circles depict patients with no biopsy sample and no clinical evidence of 
rejection. Large open circles depict biopsy procedures of kidneys lost at 90 (Fl) and 240 (F2) days. ACR=acute cellular rejection. 
of the cadaveric recipients were also given donor bone 
marrow cells. 
Three (17 '6%) of the 17 liver transplant recipients died 
of primary graft non-function (after 2 days), 
complications from sarcoidosis (171 days), and femoral-
artery haemorrhage after an interventional radiological 
procedure (181 days). No livers were lost to rejection. 
Immunosuppression for the first year (figure 7) was 
similar to the pattern for kidney recipients. Mean bilirubin 
concentration at 1 year of the 14 recipients was 
18·8 fLmollL (SD 14'7). From the fourth month onward, 
between 10 and 12 of the 14 liver recipients needed only 
spaced monotherapy (figure 7). Late rejections during and 
after the first year usually were treated with one or two 
boluses of prednisone or reduction of the intervals 
between tacrolimus doses. 
Minimum use of immunosuppression has greatly 
facilitated management of patients with confounding 
factors, of which the most common was recurrent 
hepatitis (five of 14 survivors). At 13-17 months, dose 
frequencies were every other day (n=2), three per week 
(4), two per week (2), and one per week (3). 
Pancreas transplantation 
The 14 patients, who had been insulin dependent for 
many years, received crossmatch-negative cadaveric 
allografts which were transplanted alone (n=4) or with the 
kidney from the same donor (n=lO, see above). Two of 
the four pancreas-alone recipients, and six of the ten 
pancreas-kidney recipients, also had bone marrow cell 
infusion. One of four pancreas-alone grafts was lost to 
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rejection. Another that was transplanted with kidney was 
removed after 5 months because of arterial thrombosis, 
without harm to the renal graft. 
In what we deemed protocol violations, the pancreas 
recipients were frequently treated with multiple drugs in 
response to rises in lipase concentration (see above). 
Nevertheless, five of 12 patients with normally 
functioning pancreas (table 3) are on spaced doses of 
tacrolimus mono therapy: every other day en=l), three 
times a week (2), and once a week (2). 
Intestine transplantation 
All 11 bowel recipients had chronic intestinal 
failure from non-neoplastic diseases. Small intestinal 
allografts were transplanted alone in nine patients 
or as a component of multivisceral allografts that included 
the liver in two. Mean HLA mismatches were 4·7 
(SD 0'9). Nine allografts, including the two that consisted 
of multiple organs, had ex-vivo bowel irradiation 
(7'5 Gy). Recipients of these nine grafts were given an 
infusion of 2'4-9'OX los/kg donor bone marrow cells 
within the subsequent 24 h.'o The two recipients of non-
irradiated intestine were not given adjunct bone marrow. 
All 11 patients, and eight (73%) of the 11 grafts, 
survived. Difficulties in dosing resulted in a mean 
tacrolimus trough concentration of 20·4 fLg/L (SD 2'1) 
during the first 30 days. Although this was twice the 
stipulated target and thus a systematic protocol violation, 
six of the eight patients with surviving grafts are on 
spaced-doses of tacrolimus: every other day (n=3), three 
times a week (1), and twice a week (2). Two of the three 
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Figure 7: Four categories of treatment in the first 12 months for 14 liver recipients who survive after 13-17 months 
Note that the proportion of people who needed category 3 and 4 immunosuppression during the first 60 days was comparable with that in the kidney 
recipients (figure 4). 
patients who lost intestine-only grafts had successful 
retransplantation, leaving only one of the 11 dependent 
on parenteral hyperalimentation. 
Discussion 
Our findings suggest that improvements in clinical 
transplantation might be within easy grasp by 
simple modification of the timing and dosage of 
immunosuppression. Clinical or histopathological 
evidence of immune activation has been widely thought 
to be categorically undesirable, and the equivalent 
of rejection. Instead, rejection and tolerance are 
stages of the same continuum in the notion from which 
our treatment algorithm derived.24•11 Thus, immune 
activation at any point on the immune response curve 
shown in figure 8 could theoretically represent a stage 
in the evolution of immunological tolerance rather 
than predicting graft loss. In this view, organ 
engraftment entails the same mechanisms as bone-
marrow engraftment, beginning with contemporaneous 
host-versus-graft and graft-versus-host reactions. These 
responses reach peak intensity in the first few weeks 
post-transplant, and might be manifested clinically 
as graft-versus-host disease, rejection, or both 
simultaneously. 
n Survival Spaced weaning; 
Patient Graft surviving grafts 
Transplant 
Intestine 11 11 (100%) 8(73%) 6/8 (75%) 
Pancreas 14 14 (100%) 12 (86%) 5/12 (42%) 
Total 25 25 20 (80%) 11/20 (55%) 
Table 3: Patients' and graft survival and incidence of weaning 
in intestine and pancreas recipients at end of study 
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The usually dominant host-versus-graft response of 
the organ recipient is induced by migration to host 
lymphoid organs of the graft's passenger leucocytes. 2- 4,1I 
If the response cannot eliminate the mobile donor 
leucocytes (and the source organ graft), it may 
be exhausted and deleted (figure 8). The response 
can be reduced into a more easily deletable range 
by pretreatment with many immunosuppressive 
modalities. 12,13 This was accomplished in our patients 
with a polyc1onal antithymocyte globulin. 7 Other 
antilymphoid antibody preparations are expected to be 
effective, including the humanised monoclonal antibody, 
alemtuzumab, used for cadaver-kidney recipients by 
CaIne and colleagues l4 as part of a steroid-sparing 
regimen based on ciclosporin. 
However, pretreatment alone is not enough to 
permit alloengraftment in most experimental models, or 
in humans. The aim of minimum post-transplant 
immunosuppression is to further reduce the clonal 
response with just enough treatment to prevent 
irreversible immune damage to the graft (figure 8), 
but not with such heavy treatment that the donor-
specific clonal exhaustion-deletion is precluded. Thus, 
the common practice of beginning multiagent 
immunosuppression at the time of transplantation is 
potentially antitolerogenic (figure 8). Results of direct 
experimentation have shown, in various models, that 
tacrolimus or ciclosporin/5- 17 prednisone/' antilymphoid 
antibodies,l3,·9 and irradiation" in the early post-transplant 
period can abrogate production of tolerance. Moreover, 
immunosuppression theoretically can break partial 
tolerance. This occurrence was suspected in several of 
our pancreas recipients who were given a possibly 
unwarranted burst of late immunosuppression. 
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In the idea of immunosuppression-aided organ 
engraftment depicted in figure 8, the extent of weaning is 
thought to parallel the completeness with which 
tolerance was achieved. This conclusion is lent support 
by results of in-vitro immunological studies at 1 year in 
kidney reCIpIents who were on spaced doses of 
tacrolimus. Moreover, our definition of tolerance as an 
active antigen-dependent process2 4.11,20 is congruent with 
the frequent biopsy finding of immune activation 
(sometimes including low-grade immune destruction) 
in well-functioning allografts. The presence after 
60 days of many donor cells in lymphoid aggregates 
of such allografts was reminiscent of experimental 
data suggesting that a transplanted organ might be a 
privileged repository for mobile donor leucocytes,21.22 
whose late traffic between non-lymphoid locations 
and lymphoid organs is a prerequisite for maintenance of 
variable tolerance induced at the outset. 3., 
The amount of immunosuppression needed during 
the critical first 60 days of most active tolerance 
was essentially the same in our kidney and liver 
recipients. This observation does not lend support to 
the widely held view that the transplanted liver induces 
a weaker response than other organs. 23 Instead, 
it is consistent with the hypothesis that hepatic grafts 
are unusually tolerogenic because of the greater content 
of immunostimulatory-ie, inducing-passenger 
leucocytes.' 4,11.20 Not surprisingly, the eventual rate of 
spaced weaning was highest in the liver recipients. 
The load of donor leucocytes can be increased in 
recipients of less leucocyte-endowed organs by infusion 
of donor bone-marrow cells. This extra treatment 
improves allograft survival in many experimental 
models. However, it has had little effect in clinical 
trials under conventional immunosuppression'·2'.z, 
and did not confer an advantage in our small 
subgroup of bone marrow-infused recipients under 
immunosuppression that was designed to facilitate 
tolerance mechanisms. These results do not rule out 
the possibility of promoting tolerance in organ 
recipients by donor leucocyte augmentation (including 
stem-cell transplantation), but they suggest that the 
timing and dosage of immunosuppression might be 
more important than donor-cell dose in determining the 
outcome. 
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Our ultimate objective has been to find the lowest 
maintenance drug doses consistent with stable graft 
function. We emphasise that this needs more 
sophisticated care and surveillance than conventional use 
of high-dose prophylactic immunosuppression. The 
optimum approach to weaning has yet to be fully defined. 
Instead of gradually reducing daily amounts of tacrolimus 
in our patients, we have raised the intervals between 
doses. It has been learned from historicaP" and other 
experience27 that the need for continued immuno-
suppression might approach or reach zero. In rats 
however, Murase and colleagues showed that 
maintenance doses of tacrolimus, given as infrequently as 
once per week, can sustain low-level microchimerism 
and prevent otherwise inexorable chronic rejection of 
organ allografts. II In view of such evidence, weaning 
beyond once a week doses of tacrolimus has not been 
recommended to our patients. 
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